Discovery of a Novel Site Regulating Glucokinase Activity following Characterization of a New Mutation Causing Hyperinsulinemic Hypoglycemia in Humans

被引:20
作者
Beer, Nicola L. [1 ]
van de Bunt, Martijn [1 ]
Colclough, Kevin [2 ]
Lukacs, Christine [3 ]
Arundel, Paul [5 ]
Chik, Constance L. [6 ]
Grimsby, Joseph [4 ]
Ellard, Sian [7 ]
Gloyn, Anna L. [1 ]
机构
[1] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England
[2] Royal Devon & Exeter Natl Hlth Serv NHS Fdn, Dept Mol Genet, Exeter EX2 5AD, Devon, England
[3] Hoffmann La Roche Inc, Dept Discovery Technol, Nutley, NJ 07110 USA
[4] Hoffmann La Roche Inc, Dept Metab Dis, Nutley, NJ 07110 USA
[5] Sheffield Childrens Natl Hlth Serv NHS Fdn Trust, Sheffield S10 2TH, S Yorkshire, England
[6] Univ Alberta, Div Endocrinol & Metab, Edmonton, AB T6G 2S2, Canada
[7] Univ Exeter, Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX2 5DW, Devon, England
基金
英国医学研究理事会;
关键词
NEONATAL DIABETES-MELLITUS; PANCREATIC BETA-CELLS; YOUNG TYPE-2 MODY-2; PLASMA-GLUCOSE; ACTIVATOR RO4389620; FASTING GLUCOSE; PROTEIN; PREVALENCE; CHILDREN; OVEREXPRESSION;
D O I
10.1074/jbc.M111.223362
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Type 2 diabetes is a global problem, and current ineffective therapeutic strategies pave the way for novel treatments like small molecular activators targeting glucokinase (GCK). GCK activity is fundamental to beta cell and hepatocyte glucose metabolism, and heterozygous activating and inactivating GCK mutations cause hyperinsulinemic hypoglycemia (HH) and maturity onset diabetes of the young (MODY) respectively. Over 600 naturally occurring inactivating mutations have been reported, whereas only 13 activating mutations are documented to date. We report two novel GCK HH mutations (V389L and T103S) at residues where MODY mutations also occur (V389D and T103I). Using recombinant proteins with in vitro assays, we demonstrated that both HH mutants had a greater relative activity index than wild type (6.0 for V389L, 8.4 for T103S, and 1.0 for wild type). This was driven by an increased affinity for glucose (S-0.5, 3.3 +/- 0.1 and 3.5 +/- 0.1 mM, respectively) versus wild type (7.5 +/- 0.1 mM). Correspondingly, the V389D and T103I MODY mutants had markedly reduced relative activity indexes (<0.1). T103I had an altered affinity for glucose (S-0.5, 24.9 +/- 0.6 mM), whereas V389D also exhibited a reduced affinity for ATP and decreased catalysis rate (S-0.5, 78.6 +/- 4.5 mM; ATP(Km), 1.5 +/- 0.1 mM; K-cat, 10.3 +/- 1.1s(-1)) compared with wild type (ATP(Km), 0.4 +/- <0.1; K-cat, 62.9 +/- 1.2). Both Thr-103 mutants showed reduced inhibition by the endogenous hepatic inhibitor glucokinase regulatory protein. Molecular modeling demonstrated that Thr-103 maps to the allosteric activator site, whereas Val-389 is located remotely to this position and all other previously reported activating mutations, highlighting alpha -helix 11 as a novel region regulating GCK activity. Our data suggest that pharmacological manipulation of GCK activity at locations distal from the allosteric activator site is possible.
引用
收藏
页码:19118 / 19126
页数:9
相关论文
共 72 条
[1]
Evidence that glucokinase regulatory protein is expressed and interacts with glucokinase in rat brain [J].
Alvarez, E ;
Roncero, I ;
Chowen, JA ;
Vázquez, P ;
Blázquez, E .
JOURNAL OF NEUROCHEMISTRY, 2002, 80 (01) :45-53
[2]
Cell biology assessment of glucokinase mutations V62M and G72R in pancreatic β-cells -: Evidence for cellular instability of catalytic activity [J].
Arden, Catherine ;
Trainer, Alison ;
de la Iglesia, Nuria ;
Scougall, Kathleen T. ;
Gloyn, Anna L. ;
Lange, Alex J. ;
Shaw, James A. M. ;
Matschinsky, Franz M. ;
Agius, Loranne .
DIABETES, 2007, 56 (07) :1773-1782
[3]
*ARR BIOPHARMA INC, 2009, GLUC ACT ARRY 403 PH
[4]
Interaction of glucokinase with the liver regulatory protein is conferred by leucine-asparagine motifs of the enzyme [J].
Baltrusch, S ;
Francini, F ;
Lenzen, S ;
Tiedge, M .
DIABETES, 2005, 54 (10) :2829-2837
[5]
Characterization of glucokinase-binding protein epitopes by a phage-displayed peptide library - Identification of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase as a novel interaction partner [J].
Baltrusch, S ;
Lenzen, S ;
Okar, DA ;
Lange, AJ ;
Tiedge, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (47) :43915-43923
[6]
Opposite Clinical Phenotypes of Glucokinase Disease: Description of a Novel Activating Mutation and Contiguous Inactivating Mutations in Human Glucokinase (GCK) Gene [J].
Barbetti, Fabrizio ;
Cobo-Vuilleumier, Nadia ;
Dionisi-Vici, Carlo ;
Toni, Sonia ;
Ciampalini, Paolo ;
Massa, Ornella ;
Rodriguez-Bada, Pablo ;
Colombo, Carlo ;
Lenzi, Lorenzo ;
Garcia-Gimeno, Maria A. ;
Bermudez-Silva, Francisco J. ;
Rodriguez de Fonseca, Fernando ;
Banin, Patrizia ;
Aledo, Juan C. ;
Baixeras, Elena ;
Sanz, Pascual ;
Cuesta-Munoz, Antonio L. .
MOLECULAR ENDOCRINOLOGY, 2009, 23 (12) :1983-1989
[7]
The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver [J].
Beer, Nicola L. ;
Tribble, Nicholas D. ;
McCulloch, Laura J. ;
Roos, Charlotta ;
Johnson, Paul R. V. ;
Orho-Melander, Marju ;
Gloyn, Anna L. .
HUMAN MOLECULAR GENETICS, 2009, 18 (21) :4081-4088
[8]
Allosteric activation of human glucokinase by free polyubiquitin chains and its ubiquitin-dependent cotranslational proteasomal degradation [J].
Bjorkhaug, Lise ;
Molnes, Janne ;
Sovik, Oddmund ;
Njolstad, Pal Rasmus ;
Flatmark, Torgeir .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (31) :22757-22764
[9]
Bonadonna RC, 2008, DIABETOLOGIA, V51, pS371
[10]
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study [J].
Bonadonna, Riccardo C. ;
Heise, Tim ;
Arbet-Engels, Christophe ;
Kapitza, Christoph ;
Avogaro, Angelo ;
Grimsby, Joe ;
Zhi, Jay ;
Grippo, Joseph F. ;
Balena, Raffaella .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (11) :5028-5036